Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues
- 28 February 1999
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 35 (2), 320-324
- https://doi.org/10.1016/s0959-8049(98)00372-4
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerAnnals of Oncology, 1997
- Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanomaAnnals of Oncology, 1997
- A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG)Annals of Oncology, 1996
- The experimental development of bioreductive drugs and their role in cancer therapyCancer and Metastasis Reviews, 1993
- Immunohistochemical localization of carbonyl reductase in human tissues.Journal of Histochemistry & Cytochemistry, 1992
- Carbonyl reductase from human testis: purification and comparison with carbonyl reductase from human brain and rat testisBiochimica et Biophysica Acta (BBA) - General Subjects, 1992
- Carbonyl reductase provides the enzymatic basis of quinone detoxication in manBiochemical Pharmacology, 1986
- Reductases for carbonyl compounds in human liverBiochemical Pharmacology, 1985
- Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian liversBiochemical Pharmacology, 1978
- Prostaglandin MetabolismPublished by Elsevier BV ,1974